Home  |  Contact

Cellosaurus LoVo/DR5 (CVCL_6C49)

Cell line name LoVo/DR5
Accession CVCL_6C49
Resource Identification Initiative To cite this cell line use: LoVo/DR5 (RRID:CVCL_6C49)
Comments Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Sequence variations Homozygous for ACVR2A p.Lys437fs*5 (c.1310delA) (from parent cell line).
APC p.Arg1114Ter (c.3340C>T), p.Met1431fs*42 (c.4289delC) and p.Arg2816Gln (c.8447G>A) (from parent cell line).
KRAS p.Gly13Asp (c.38G>A) (from parent cell line).
SMAD2 p.Ala292Val (c.875C>T) (from parent cell line).
Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0399 (LoVo)
Sex of cell Male
Age at sampling 56Y
Category Cancer cell line
Publications

PubMed=2896069
Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M.
Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Cancer Res. 48:2793-2797(1988)

PubMed=1673331
Slovak M.L., Coccia M., Meltzer P.S., Trent J.M.
Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Anticancer Res. 11:423-428(1991)

Cross-references
Other Wikidata; Q54902904